CrossRef

Untitled

The Effect of Treatment and Bone Metabolic Factors on Fracture Incidence in Patients with Thalassemia-Induced Osteoporosis: An Observational Study

Current Drug Therapy 15(4) (2020)

Athanasios N. Tsartsalis; George I. Lambrou; Eugenia Vlachou; Athanasia Samartzi; George P. Chrousos; Christina Kanaka-Gantenbein; Antonis Kattamis

Open Reduction Internal Fixation vs Primary Arthrodesis for Lisfranc Fracture-Dislocations: A Cost Analysis

Foot & Ankle Orthopaedics 9(1) (2024)

Arinze Ochuba; Christopher J. Murdock; Amy L. Xu; Morgan Snow; Jessica Schmerler; Christopher R. Leland; Claire McDaniel; John Thompson; Amiethab A. Aiyer

Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis

Osteoporosis International 33(1) (2022)

Friederike Thomasius; Santiago Palacios; Asif Alam; Mitra Boolell; Francis Vekeman; Geneviève Gauthier

Pharmacotherapy change patterns after fragility fracture in patients receiving bone-active medication: a fracture liaison service quality improvement cohort study

BMC Musculoskeletal Disorders 27(1) (2026)

Hina Ansari; Alan Yang; Rebeka Sujic; Earl R. Bogoch; Victoria Elliot-Gibson; Ravi Jain; Jennifer Weldon; Denise Linton; Joanna E.M. Sale

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA

Osteoporosis International 34(5) (2023)

John A. Eisman; Bernard Cortet; Mitra Boolell; Raluca Ionescu-Ittu; Francis Vekeman; Julie Heroux; Friederike Thomasius

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis

Osteoporosis International 36(6) (2025)

Charlotte Beaudart; Nicola Veronese; Jonathan Douxfils; Jotheeswaran Amuthavalli Thiyagarajan; Francesco Bolzetta; Paolo Albanese; Gianpaolo Voltan; Majed Alokail; Nicholas C. Harvey; Nicholas R. Fuggle; Olivier Bruyère; René Rizzoli; Jean-Yves Reginster